Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Role Of Trastuzumab In The Management Of HER2-positive Metastatic Breast Cancer: An Updated Review

Y. Tokuda, Y. Suzuki, Y. Saito, S. Umemura
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Currently, trastuzumab is one of the key drugs in the treatment strategy for HER2-positive breast cancer. Although metastatic breast cancer is unlikely to be cured, some HER2-positive patients have survived for a long time with complete response to trastuzumab therapy. In HER2-positive metastatic breast cancer, single agent trastuzumab is effective and less toxic. Combination of trastuzumab with cytotoxic drugs is also effective. Therefore, major guidelines recommend using trastuzumab as a key drug in the management of HER2-positive metastatic breast cancer. However, many clinical questions still need to be solved. In this article, recent evidence was reviewed to find some answers about these issues.
This paper references
Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin
T. Suzuki (2004)
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
M. De Laurentiis (2008)
Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study
J. Cortés (2009)
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
C. Carlomagno (1996)
Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series.
A. Bardia (2006)
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
R. Pietras (1995)
Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05)
G. V. Minckwitz (2008)
What's going on HER2過剰発現転移性乳がんに対するトラスツズマブとビノレルビンあるいはタキサン併用療法試験[Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP 'Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane
柏葉 匡寛 (2007)
Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study.
H. Burstein (2006)
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
M. Pegram (1999)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
M. Untch (2004)
A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy
J. O'shaughnessy (2008)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
A. Buzdar (2005)
Enhanced anti-tumor effect of trastuzumab combined with less cardiotoxic anthracycline, amrubicin, in a HER2-positive human cancer xenograft in athymic mice
Y. Tokuda (2008)
In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product.
Y. Tokuda (1996)
Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study)
M. Bontenbal (2008)
Randomized phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer.
K. Najagami (2009)
A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody.
M. Ohta (2001)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
M. Marty (2005)

This paper is referenced by
Developing RNA diagnostics for studying healthy human ageing
Sanjana Sood (2017)
Photochemical internalization (PCI) of HER2-targeted toxins: synergy is dependent on the treatment sequence.
M. Berstad (2012)
Adenovirus targeting for gene therapy of pancreatic cancer
M. V. Geer (2011)
In vivo targeting of HER2-positive tumor using 2-helix affibody molecules
Gang Ren (2011)
Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer
Yiwen You (2018)
Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy
Sohita Dhillon (2014)
Photochemical internalization of recombinant toxins targeting EGFR and HER2 for treatment of aggressive and resistant cancers
M. Berstad (2015)
A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients
B. Zhu (2015)
Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.
V. Papadimitrakopoulou (2012)
Effects of a Combined Treatment With GPR30 Agonist G-1 and Herceptin on Growth and Gene Expression of Human Breast Cancer Cell Lines
Julia Lubig (2012)
Drug Treatment of Cancer Cell Lines: A Way to Select for Cancer Stem Cells?
I. Chiodi (2011)
Small Activating RNA Restores the Activity of the Tumor Suppressor HIC-1 on Breast Cancer
F. Zhao (2014)
Additive effects of trastuzumab and genistein on human breast cancer cells
C. Lattrich (2011)
Semantic Scholar Logo Some data provided by SemanticScholar